聚乙二醇化重组人粒细胞集落刺激因子在恶性肿瘤化疗后骨髓抑制患者中的应用

陈琰; 陈坚; 张建华

doi:10.7619/jcmp.201923018

聚乙二醇化重组人粒细胞集落刺激因子在恶性肿瘤化疗后骨髓抑制患者中的应用

Application of pegylated recombinant humangranulocyte-colony stimulating factor in myelosuppression after chemotherapy for malignant tumor

摘要

摘要:
目的探讨聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在恶性肿瘤化疗后骨髓抑制患者中的应用效果。
方法将入院接受全身化疗的30例恶性肿瘤患者作为研究对象，每次化疗结束后48~72 h, 结合患者体质量、经济情况及原有骨髓抑制的严重程度，酌情给予3 mg或6 mg PEG-rhG-CSF皮下注射1次。
结果 30例患者中, 6例每次注射6 mg, 24例每次注射3 mg。化疗后患者均未出现3~4度骨髓抑制; 6例出现1度粒细胞减少, 3例出现2度粒细胞减少。30例患者均未出现严重并发症。
结论恶性肿瘤患者全身化疗后应用PEG-rhG-CSF预防粒细胞减少疗效确切，可结合患者的体质量、经济情况及原有骨髓抑制的严重程度调整剂量。

Abstract:
Objective To investigate the effect of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) on myelosuppression after chemotherapy for malignant tumor.
Methods Totally 30 patients with systemic chemotherapy for malignant tumor were included in this study, and were given subcutaneous injection of PEG-rhG-CSF for a single dosage of 3 or 6 mg per time at 48 to 72 h after chemotherapy according to the body mass index, financial burden and severity of myelosuppression.
Results Out of 30 patients, 6 patients were given a dosage of 6 mg per time, 24 were given a dosage of 3 mg per time. None of patients developed 3 to 4 grade myelosuppression, but 6 cases occurred grade 1 granulocytopenia and 3 with grade 2 granulocytopenia.
Conclusion The subcutaneous injection of PEG-rhG-CSF can effectively prevent the granulocytopenia induced by chemotherapy. The dosage of PEG-rhG-CSF should be adjusted according to the body mass index, financial burden and severity of myelosuppression.

HTML全文

参考文献(11)

施引文献

资源附件(0)